NRG-HN004 Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin.

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Locoregionally Advanced Head And Neck Cancer
  • Age: Between 18 years - 100 years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    In order to participate in this study, the following criteria must be met: 1) You must have the psychological ability and general health that permits completion of the study requirements1) and required follow up. 2) You must have pathologically confirmed, previously untreated, unresected squamous ell carcinoma of the larynx, hypopharynx, oropharynx, oral cavity, or carcinoma of unknown head/neck primary within 60 days prior to Step 1 registration.

You may not be eligible for this study if the following are true:

  • You will not be able to participate in this study if: 1) You have prior invasive malignancy within the past 3 years (except for non-melanomatous skin cancer, and early stage treated prostate cancer 2) You have Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields 3) You have Prior systemic therapy, including cytotoxic chemotherapy, biologic/targeted therapy, or immune therapy for the study cancer


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.